Status:
UNKNOWN
Chinese Medicine for Patients With Psoriasis
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Psoriasis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Psoriasis is an inflammatory skin disease with huge negative impact on the quality of life of the patients, and has an overall prevalence of 2% to 3% in the general population. Plaques psoriasis is th...
Detailed Description
Psoriasis is an inflammatory skin disease with huge negative impact on the quality of life of the patients, and has an overall prevalence of 2% to 3% in the general population. Plaques psoriasis is th...
Eligibility Criteria
Inclusion
- Mild to moderate chronic plaque psoriasis (PASI score 3 to 12).
- Willingness to give informed consent.
Exclusion
- Pustular or generalized erythrodermic psoriasis.
- Psoriatic arthritis with syndrome of spleen-kidney yang deficiency according to Chinese medicine theory.
- Systemic therapy for psoriasis 6 months prior to baseline.
- Use topical medications for psoriasis 14 days prior to baseline such as retinoids, corticosteroids, vitamin D analogues, tazarotene and tacrolimus.
- Has taken any antibiotics, probiotics and prebiotics 30 days prior to baseline.
- UV light therapy 30 days prior to baseline.
- Clinically significant laboratory abnormality in blood, liver or renal functions (≥1.5 times the upper limit of reference range).
- History of allergy to Chinese herbs.
- Unwillingness to comply with study protocol.
- Any other condition that in the opinion of the investigators could compromise the study.
Key Trial Info
Start Date :
March 20 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05295979
Start Date
March 20 2023
End Date
August 31 2024
Last Update
July 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hong Kong Institute of Integrative Medicine
Hong Kong, Hong Kong